Industry news

  • 23 January 2018

    Mandatory labeling for 7 nosologies may be introduced in 2018

    GMP News

    In 2020, the labeling of medicinal products will become mandatory for all manufacturers. But, for some drugs, including the expensive medicines, it may happen as early as in 2018. This was announced by Mikhail Murashko, the Head of Roszdravnadzor.

  • 23 January 2018

    Exports of medical products will become one of the main areas for Pharma 2030

    GMP News

    The exports of Russian medical products will be one of the main areas of activities in the next decade, said Sergey Tsyb, the Deputy Minister of Industry and Trade of the Russian Federation.

  • 22 January 2018

    API market will reach a value of $239.8 billion by 2025

    GMP News

    According to the report, recently published by Million Insights, the global Active Pharmaceutical Ingredient (API) market size was worth at USD 134.2 billion in the year 2015 which is anticipated to reach a value of $239.8 billion by 2025, with CAGR of 6.0%. Rising prevalence of chronic diseases such as neurological diseases, cardiovascular diseases, can lead to the growth.

  • 22 January 2018

    Russian government to subsidize labeling costs of pharma producers

    Remedium

    The Russian government has announced that it will provide subsidies for domestic drugmakers and foreign companies operating in the local market for the partial cover their costs, associated with the forthcoming introduction of labeling procedure in the domestic pharmaceutical market, reports The Pharma Letter’s local correspondent. 

  • 19 January 2018

    New research showed a trouble with clarity of drug approvals in Central Europe

    GMP News

    New research, from an international group of health policy experts led by the University of Bath (UK), reports a mixed picture of transparency in public decisions-making around new medicine approvals in Poland, one of Europe’s largest pharmaceutical markets.

  • 19 January 2018

    Japanese pharma Ц no longer Сlost in translationТ

    GMP News

    A New Year report from CPhI forecasts 2018 will be a transformative year for Japanese pharma as the market evolves towards growth in generics, biosimilars and increased internationalisation. The CPhI Japan 2018 report – released ahead of what is likely to be the largest ever CPhI Japan (18-20 April, 2018) – has identified that demographic pressures on healthcare costs are driving a political agenda that will benefit players with lower costs solutions. 

  • 18 January 2018

    Russian President signs the Federal Law on introduction of drug labeling

    GMP News

    Russian President Vladimir Putin signed the Federal Law “On amendments to the Federal law “On Circulation of medicines.” The law provides for the establishment of state information system to monitor the movement of medicinal products for human use from the manufacturer to the final consumer by using the means of identification with regard to medicinal products in order to ensure the quality control of medicinal products for human use, that are in circulation, and protect the legal trade from falsified, counterfeit, and substandard medicines.

  • 18 January 2018

    Russia has one of the shortest periods for expert examination of medicines

    GMP News

    Elena Maksimkina, the Director of the Department of Drug Supply and Regulation of Medical Devices at the Russian Ministry of Health, gave her assessment of the pharmaceutical market in Russia.

  • 17 January 2018

    New tools for turning genes into drug factories

    Arlene Weintraub / FierceBiotech

    Synthetic biologists have long dreamed of designing genetic circuits in the body that can produce drugs in response to environmental cues. But it’s been a challenging task. Now scientists at Rice University say they’ve created a toolkit of gene “promoters” that can turn genes on and off at command.

  • 17 January 2018

    FDA approves first treatment for breast cancer with a certain inherited genetic mutation

    U.S. Food and Drug Administration

    The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news